Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Change in Cash (2016 - 2025)

Historic Change in Cash for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to -$917.8 million.

  • Dexcom's Change in Cash fell 597814.57% to -$917.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $311.8 million, marking a year-over-year increase of 68341.71%. This contributed to the annual value of $311.8 million for FY2025, which is 68341.71% up from last year.
  • Per Dexcom's latest filing, its Change in Cash stood at -$917.8 million for Q4 2025, which was down 597814.57% from $676.6 million recorded in Q3 2025.
  • Dexcom's 5-year Change in Cash high stood at $676.6 million for Q3 2025, and its period low was -$917.8 million during Q4 2025.
  • For the 5-year period, Dexcom's Change in Cash averaged around $5.0 million, with its median value being -$17.0 million (2023).
  • Its Change in Cash has fluctuated over the past 5 years, first soared by 286217.62% in 2023, then tumbled by 597814.57% in 2025.
  • Over the past 5 years, Dexcom's Change in Cash (Quarter) stood at -$391.6 million in 2021, then surged by 85.75% to -$55.8 million in 2022, then tumbled by 38.53% to -$77.3 million in 2023, then soared by 80.47% to -$15.1 million in 2024, then tumbled by 5978.15% to -$917.8 million in 2025.
  • Its Change in Cash was -$917.8 million in Q4 2025, compared to $676.6 million in Q3 2025 and $254.2 million in Q2 2025.